US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Fresenius Kabi

< Previous 1 2 3 Next >
News headline image
Fresenius Kabi Receives Pharmacy Strategic Programs Excellence Award From Vizient®
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi and AABB Announce 21st Annual Blood Collectors Week, September 6–12, 2026, Honoring Lifesaving Blood Collection Professionals
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S.
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe Due to Labeling Mix-up
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
From Fresenius Kabi
Via Business Wire
News headline image
CMS Grants Fresenius Kabi COVID-19 Indication-Specific HCPCS Codes for Tyenne® (tocilizumab-aazg)
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi Recognized as a Top Employer in the United States for the Fourth Consecutive Year
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi Introduces New Presentation of Otulfi® (ustekinumab-aauz), a Biosimilar to Stelara®
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi Introduces First-Ever Rocuronium Bromide Injection Stable at Room Temperature
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi Expands Operating Room Portfolio with New Simplist® Prefilled Syringes
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi Introduces Dalbavancin for Injection (for single-dose regimen use only)
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi’s Adaptive Nomogram used on Aurora Xi Plasmapheresis System Now Operating Nationwide at BioLife Plasma Centers
From Fresenius Kabi
Via Business Wire
News headline image
CORRECTING and REPLACING Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial Due to Out-of-Specification Endotoxin Results in Certain Reserve Samples
From Fresenius Kabi
Via Business Wire
News headline image
FDA Grants Interchangeable Designation to Fresenius Kabi’s Biosimilars Conexxence® and Bomyntra® (denosumab-bnht)
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi Announces 13 New Inductees Into the National Blood Donation Hall of Fame
From Fresenius Kabi
Via Business Wire
News headline image
CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Conexxence® and Bomyntra® (denosumab-bnht)
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi Receives Two Major Awards for Supply and Service Excellence from Vizient®
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi and AABB Announce 20th Anniversary of Blood Collectors Week, September 7–14, 2025, Honoring Lifesaving Blood Collection Professionals
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Leads New EASYGEN Consortium Aimed at Decentralizing CAR-T Cell Therapy and Improving Hospital Workflows
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi Receives 2025 Premier Supplier Legacy Award
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Expands Biosimilars Portfolio With The Launch of Denosumab Biosimilars in the U.S.
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi Introduces Epinephrine Injection, USP, in 30 mg per 30 mL Multi-Dose Vials
From Fresenius Kabi
Via Business Wire
News headline image
FDA Grants Interchangeable Designation to Fresenius Kabi’s biosimilar Otulfi® (ustekinumab-aauz)
From Fresenius Kabi
Via Business Wire
News headline image
CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Otulfi® (ustekinumab-aauz)
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Receives FDA Approval for their Denosumab Biosimilars and Secures Global Settlement Agreement
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi® (ustekinumab-aauz)
From Fresenius Kabi
Via Business Wire
News headline image
Fresenius Kabi Introduces Calcitonin Salmon Injection, USP Synthetic
From Fresenius Kabi
Via Business Wire
< Previous 1 2 3 Next >